The L-arginine-nitric oxide pathway in hypertension

Current Hypertension Reports

Volumn 5, Issue 1, 2003, Pages 80-86

  Kelm, Malte ^a  

^a Medizinische Klinik und Poliklinik B   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PERINDOPRILAT; QUINAPRIL; RAMIPRIL; SIMVASTATIN;

ARTERY COMPLIANCE; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; BIOAVAILABILITY; BLOOD VESSEL DIAMETER; BLOOD VESSEL TONE; BLOOD VOLUME; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ENDOTHELIUM INJURY; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PROGENY; PROGNOSIS; RAT; REVIEW; TISSUE BLOOD FLOW; TISSUE METABOLISM; VASCULAR RESISTANCE; VASODILATATION; ADRENERGIC SYSTEM; ANIMAL; ARTERY; BLOOD PRESSURE; CORONARY ARTERY DISEASE; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; ARTERIES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NITRIC OXIDE; PROGNOSIS; VASOMOTOR SYSTEM;

EID: 0037512318     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0015-z     Document Type: Review

References (96)

1. Celermajer DS. Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol 1997, 30:325-333.
2. Bauersachs J, Popp R, Hecker M, et al.: Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996, 94:3341-3347.
3. Duffy SJ, Castle SF, Harper RW, Meredith IT: Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 1999, 100:1951-1957.
4. Heusch G, Baumgart D, Camici P, et al.: a-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000, 101:689-694.
5. Kelm M, Feelisch M, Spahr R, et al.: Quantitative and kinetic characterization of nitric oxide and EDRF release from cultured endothelial cells. Biochem Biophys Res Commun 1988, 154:236-244.
6. Kelm M, Feelisch M, Deussen A, et al.: Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc Res 1991, 25:831-836.
7. Kelm M, Feelisch M, Krebber T, et al.: Mechanisms of histamin-induced coronary vasodilation: H1-receptor-mediated release of endothelium-derived nitric oxide. J Vasc Res 1993, 30:132-138.
8. Rees DD, Palmer RMJ, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 1989, 86:3375-3378.
9. Kelm M, Schrader J: Control of coronary vascular tone by nitric oxide. Circ Res 1990, 66:1561-1575.
10. Joannides R, Richard V, Haefeli WE, et al.: Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995, 26:327-331.
11. Egashira K, Katsuda Y, Mohri M, et al.: Role of endothelium-derived nitric oxide in coronary vasodilatation induced by pacing tachycardia in humans. Circ Res 1996, 79:331-335.
12. Hoeffner U, Boulanger C, Vanhoutte PM: Proximal and distal dog coronary arteries respond differently to basal EDRF but not to NO. Am J Physiol Heart Circ Physiol 1989, 256:H828-H831.
13. Lefroy DC, Crake T, Uren NG, et al.: Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation 1993, 88:43-54.
14. Lüscher TF, Diederich D, Stebenmann R, et al.: Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988, 319:462-467.
15. Frank MW, Harris KR, Ahlin KA, Klocke FJ: Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol 1996, 27:658-663.
16. Bloch W, Hoever D, Addicks K: Stimulation of endogenous NO-production influences the dilation of the capillary microvasculature in vivo. In Biochemical, Pharmacological and Clinical Aspects of Nitric Oxide. Edited by Weissman BA, Allon N, Shapira S. London: Plenum Publishing Company Ltd; 1995:153-160.
17. Ursell PC, Mayes M: Anatomic distribution of nitric oxide synthase in the heart. Int J Cardiol 1995, 50:217-223.
18. Andries LJ, Brutsaert DL, Sys SU: Nonuniformity of endothelial constitutive nitric oxide synthase distribution in cardiac endothelium. Circ Res 1998, 82:195-203.
19. Lauer T, Preik M, Rassaf T, et al.: Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A 2001, 98:12814-12819.
20. Rassaf T, Preik M, Kleinbongard P, et al.: Vasodilator action of aqueous NO solution provides evidence for in vivo transport of bioactive NO in human plasma. J Clin Invest 2002, 109:1241-1248.
21. Minamiyama Y, Takemura S, Inoue M: Albumin is an important vascular tonus regulator as a reservoir of nitric oxide. Biochem Biophys Res Commun 1996, 225:112-115.
22. Lundberg J: Airborne nitric oxide: Inflammatory marker and aerocrine messenger in man. Acta Physiol Scand 1996, 157 (Suppl 633):1-27.
23. Pelc LR, Gross GJ, Warltier DC: Preferential increase in subendocardial perfusion produced by endothelium-dependent vasodilators. Circulation 1987, 76:191-200.
24. Chambers JW, Voss GS, Snider JR, et al.: Direct in vivo effects of nitric oxide on the coronary circulation. Am J Physiol Heart Circ Physiol 1996, 271:H1584-H1593.
25. Minamino T, Kitakaze M, Matsumura Y, et al.: Impact of coronary risk factors on contribution of nitric oxide and adenosine to metabolic coronary vasodilation in humans. J Am Coll Cardiol 1998, 31:1274-1279.
26. Quyyumi AA, Dakak N, Andrews NP, et al.: Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995, 92:320-326.
27. Pohl U, Holtz J, Busse R, Bassenge E: Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986, 8:37-44.
28. Rubanyi GM, Romero JC, Vanhoutte PM: Flow-induced release of endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 1986, 250:H1145-H1149.
29. Holtz J, Förstermann U, Pohl U, et al.: Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: Effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984, 6:1161-1169.
30. Inoue T, Tomoike H, Hisano K, Nakamura M: Endothelium determines flow-dependent dilation of the epicardial coronary artery in dogs. J Am Coll Cardiol 1988, 11:187-191.
31. Bevan JA, Joyce EH, Wellman GC: Flow-dependent dilation in a resistance artery still occurs after endothelium removal. Circ Res 1988, 63:980-985.
32. Hull SS Jr, Kaiser L, Jaffe MD, Sparks HV Jr: Endothelium-dependent flow-induced dilation of canine femoral and saphenous arteries. Blood Vess 1986, 23:183-198.
33. Miura H, Wachtel RE, Liu Y, et al.: Flow-induced dilation of human coronary arterioles. Important role of Ca2+ -activated K+ channels. Circulation 2001, 103:1992-1998.
34. Joannides R, Haefeli WE, Linder L, et al.: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319.
35. Bevan JA: Flow regulation of vascular tone. Its sensitivity to changes in sodium and calcium. Hypertension 1993, 22:273-281.
36. Shechter M, Sharir M, Labrador MJP, et al.: Oral magnesium therapy improves endothlial function in patients with coronary artery disease. Circulation 2000, 102:2353-2358.
37. Niebauer J, Cooke JP: Cardiovascular effects of exercise: role of endothelial shear stress. J Am Coll Cardiol 1996, 28:1652-1660.
38. Mullen MJ, Kharbanda RK, Cross J, et al.: Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo. Circ Res 2001, 88:145-151.
39. Dimmeler S, Fleming I, Fisslthaler B, et al.: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
40. Clarkson P, Montgomery HE, Mullen MJ, et al.: Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999, 33:1379-1385.
41. Quyyumi AA: Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998, 105:32S-39S.
42. Sessa WC, Pritchard K, Seyedi N, et al.: Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994, 74:349-353.
43. Zeiher AM, Drexler H, Saurbier B, Just H: Endothelium-mediated coronary blood flow modulation in humans. J Clin Invest 1993, 92:652-662.
44. Zeiher AM, Drexler H, Wollschläger H, Just H: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of atherosclerosis. Circulation 1991, 83:391-401.
45. Fukai T, Siegfried MR, Ushio-Fukai M, et al.: Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000, 105:1631-1639.
46. Ruschitzka FT, Wenger RH, Stallmach T, et al.: Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A 2000, 97:11609-11613.
47. Cooke JP, Dzau VJ: Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997, 96:379-382.
48. Cosentino F, Katusic ZS: Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995, 91:139-144.
49. Kelm M, Dahmann R, Wink D, Feelisch M: The nitric oxide-superoxide assay: insights into the biological chemistry of the O2/NO-interaction. J Biol Chem 1997, 272(15):9922-9932.
50. Auch-Schwelk W, Katusic ZS, Vanhoutte PM: Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension 1992, 19:442-445.
51. Traber MG, Sies H.: Vitamin E in humans: demand and delivery. Ann Rev Nutr 1996, 16:321-347.
52. McCall MR, Frei B: Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999, 26:1034-1053.
53. Spencer AP, Carson DS, Crouch MA: Vitamin E and coronary artery disease. Arch Intern Med 1999, 159:1313-1320.
54. Kelm M, Feelisch M, Krebber T, et al.: Role of nitric oxide in the regulation of coronary vascular tone in hearts from hypertensive rats. Maintenance of nitric oxide-forming capacity and increased basal production of nitric oxide. Hypertension 1995, 25:186-193.
55. Kelm M: Kardiovaskuläre Wirkungen von Stickstoffmoxid und ihre Bedeutung für die arterielle Hypertonie. Stuttgart-New York: Schattauer Verlag; 1996.
56. Nava E, Noll G, Lüscher TF: Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 1995, 91:2310-2313.
57. Taddei S, Virdis A, Ghiadoni L, Salvetti A: Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 1998, 32(Suppl 3):S41-S47.
58. Kelm M, Preik M, Hafner D, Strauer BE: Evidence for a multifactorial process involved in the impaired flow response to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension 1996, 27:346-353.
59. Feelisch M, Kelm M: Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 1991, 180:286-293.
60. Quyyumi AA, Mulcahy D, Andrews NP, et al.: Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation 1997, 95:104-110.
61. Antony I, Lerebours G, Nitenberg A: Loss of flow-dependent coronary artery dilatation in patients with hypertension. Circulation 1995, 91:1624-1628.
62. Frielingsdorf J, Kaufmann P, Seiler C, et al.: Abnormal coronary vasomotion in hypertension: role of coronary artery disease. J Am Coll Cardiol 1996, 28:935-941.
63. Houghton JL, Davison CA, Kuhner PA, et al.: Heterogeneous vasomotor responses of coronary conduit and resistance vessels in hypertension. J Am Coll Cardiol 1998, 31:374-382.
64. Ruschitzka FT, Corti R, Noll G, Lüscher TF: A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999, 17(Suppl 1):S25-S35.
65. Ruschitzka FT, Noll G, Lüscher TF: Combination of ACE inhibitors and calcium antagonists: a logical approach. J Cardiovasc Pharmacol 1998, 31(Suppl 2):S5-S16.
66. Yusuf S, Sleight P, Pogue J, et al.: Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
67. Kuga T, Mohri M, Egashira K, et al.: Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 1997, 30:108-112.
68. Usui M, Egashira K, Tomita H, et al.: Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000, 101:305-311.
69. Mancini GBJ: Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med 1998, 105(1A):40S-47S.
70. Cannon RO III: Potential mechanisms for the effect of angiotensin-converting enzyme inhibitors on endothelial dysfunction: the role of nitric oxide. Am J Cardiol 1998, 82(Suppl 10A):8S-10S.
71. Antony I, Lerebours G, Nitenberg A: Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996, 94:3115-3122.
72. Prasad A, Husain S, Quyyumi AA: Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition. A potential role of bradykinin. J Am Coll Cardiol 1999, 33:796-804.
73. Mancini GBJ, Henry GC, Macaya C, et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996, 94:258-265.
74. Pitt B, Byrington RP, Furberg CD, et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000, 102:1503-1510.
75. Frielingsdorf J, Seiler C, Kaufmann P, et al.: Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996, 93:1380-1387.
76. Kaufmann PA, Frielingsdorf J, Mandinov L, et al.: Reversal of abnormal coronary vasomotion by calcium antagonists in patients with hypercholesterolemia. Circulation 1998, 97:1348-1354.
77. Kitakaze M, Asanuma H, Takashima S, et al.: Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs. Circulation 2000, 101:311-317.
78. Verhaar MC, Honing MLH, van Dam T, et al.: Nifedipine improves endothelial function in hyperchloesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res 1999, 42:752-760.
79. Zhang X, Recchia FA, Bernstein R, et al.: Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J Pharmacol Exp Ther 1999, 288:742-751.
80. Kobayashi N, Yanaka H, Tojo A, et al.: Effects of amiodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. J Cardiovasc Pharmacol 1999, 34:173-181.
81. Kitakaze M, Node K, Minamino T, et al.: A Ca channel blocker, benidipine, increases coronary blood flow and attenuates the severity of myocardial ischemia via NO-dependent mechanisms in dogs. J Am Coll Cardiol 1999, 33:242-249.
82. Ruschitzka FT, Lüscher TF: Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?. Am Heart J 1997, 134:S31-S47.
83. Parent R, Al-Obaidi M, Lavallee M: Nitric oxide formation contributes to adrenergic dilation of resistance coronary vessels in conscious dogs. Circ Res 1993, 73:241-251.
84. Dandona P, Karne R, Ghanim H, et al.: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000, 101:122-124.
85. Heitzer T, Schlinzig T, Krohn K, et al.: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
86. Perticone F, Ceravolo R, Pujia A, et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191-196.
87. Schächinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
88. Suwaidi JA, Hamasaki S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
89. Schächinger V, Britten MB, Zeiher AM: Impaired epicardial coronary vasoreactivity predicts for adverse cardiovascular events during long-term follow-up. Circulation 1999, 100 (Suppl I):I-54.
90. Bonnardeaux A, Nadaud S, Charru A, et al.: Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation 1995, 91:96-102.
91. Glenn CL, Wang WYS, Morris BJ: Different frequencies of inducible nitric oxide synthase genotypes in older hypertensives. Hypertension 1999, 33:927-932.
92. Kato N, Sugiyama T, Morita H, et al.: Lack of evidence for association between the endothelial nitric oxide synthase gene and hypertension. Hypertension 1999, 33:933-936.
93. Cox DA, Vita JA, Treasure CB, et al.: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989, 80:458-465.
94. Clarkson P, Celermajer DS, Powe AJ, et al.: Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997, 96:3378-3383.
95. Gaeta G, De Michele M, Cuomo S, et al.: Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000, 343:840-846.
96. Taddei S, Virdis A, Mattei P, et al.: Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996, 94:1298-1303.